You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 15, 2026

Drug Price Trends for FT GAS RELIEF


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for FT GAS RELIEF

Average Pharmacy Cost for FT GAS RELIEF

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
FT GAS RELIEF(SIMETH) 80 MG CHW 70677-1067-02 0.03242 EACH 2026-03-18
FT GAS RELIEF 125 MG CHEW TAB 70677-1077-01 0.10214 EACH 2026-03-18
FT GAS RELIEF 125 MG SOFTGEL 70677-1092-01 0.06907 EACH 2026-03-18
FT GAS RELIEF(SIMETH) 80 MG CHW 70677-1067-01 0.03242 EACH 2026-03-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

FT GAS RELIEF Market Analysis and Financial Projection

Last updated: February 14, 2026

Market Analysis and Price Projections for FT Gas Relief

Current Market Landscape

FT Gas Relief is an over-the-counter gastrointestinal product primarily used for the relief of bloating, gas, and indigestion. Its market environment remains competitive, with multiple branded and generic formulations available.

Key competitors include:

  • Simethicone-based products (e.g., Gas-X, Phazyme)
  • Combinations with simethicone and antacids
  • Natural and herbal remedies

The global anti-gas product market was valued at approximately $900 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of about 4.2% through 2027 ([1]).

Market Penetration and Consumer Demand

Factors influencing demand:

  • Rising awareness of gastrointestinal health
  • Increased consumption of processed foods leading to more gas-related issues
  • Growth in aging populations more prone to digestive problems
  • Accessibility of OTC products in brick-and-mortar stores and online

FT Gas Relief’s penetration is currently limited but expected to expand as marketing efforts increase and distribution channels strengthen.

Regulatory Environment

In the U.S., FT Gas Relief is classified as a dietary supplement or OTC drug depending on its formulation. Regulatory approval for new formulations or formulations with new claims requires FDA clearance, which influences time-to-market and development costs.

Price Trends and Projections

Current retail prices for gas relief products average between $8 and $15 per box containing 30 to 50 capsules or tablets:

Product Type Typical Price Range Packaging Size Dosage Form
Simethicone brands $8 - $12 30 – 50 capsules Capsules
Combination products $10 - $15 30 – 100 tablets Tablets

These prices are consistent across major pharmacy chains and online outlets.

Price Projections (Next 5 Years)

  • Base Scenario: If FT Gas Relief maintains current formulation and marketing without significant innovation, its price is expected to stay within the $8–$15 range, adjusted for inflation and competitive pressures.

  • Optimistic Scenario: Introduction of improved formulations, such as combination products with added probiotic effects, could command premium pricing up to $20 per package. Market exclusivity or branding investments could enable short-term price premiums.

  • Pessimistic Scenario: If competing generics drive prices downward or regulatory barriers slow product launches, prices may decline by 10–15%, settling around $7–$13 per package.

Investment and Cost Considerations

Development costs for new formulations range from $2 million to $10 million, depending on complexity and regulatory pathway ([2]). Price adjustments will also depend on manufacturing costs, which for OTC products are approximately $0.20–$0.50 per capsule/tablet.

Market Entry Barriers

  • Patent status: Existing patents on key formulations could limit competition.
  • Regulatory approval: Stringent standards for claims and safety data prolong product development.
  • Brand loyalty: Consumers tend to stick with established brands, hindering new entrants.

Strategic Outlook

To increase market share and justify higher price points:

  • Invest in differentiated formulations.
  • Enhance marketing to build consumer awareness.
  • Develop distribution channels, especially e-commerce.

Key Takeaways

  • The global anti-gas market is expanding at 4.2% CAGR through 2027.
  • Current retail prices for gas relief products range from $8 to $15.
  • Price stability expected unless significant innovation or market shifts occur.
  • Targeted product differentiation and strategic marketing can provide competitive advantages.
  • Regulatory pathways and patent protections significantly influence pricing and market entry.

FAQs

1. What is the primary active ingredient in FT Gas Relief?
Simethicone, which reduces surface tension of gas bubbles, facilitating their break-up and expulsion.

2. How does FT Gas Relief compare price-wise to competitors?
Prices are similar, averaging $8–$15 per package, with little variation unless new formulations command premiums.

3. What factors could shift price projections?
Market competition, regulatory changes, formulation innovations, and manufacturing cost fluctuations.

4. Can patent protection influence FT Gas Relief’s marketability?
Yes. Patents on specific formulations or delivery methods can extend market exclusivity and price control.

5. What growth opportunities exist for FT Gas Relief?
Introducing novel formulations, expanding online distribution, and strengthening branding efforts.


References

[1] MarketsandMarkets, “Over-the-Counter (OTC) Drugs Market,” 2022.
[2] EvaluatePharma, “Drug Development Costs and Timelines,” 2021.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.